Title:Peanut Resveratrol Inhibits COX-2 in Ehrlich Ascites Carcinoma In vivo
Model
Volume: 19
Issue: 3
Author(s): Hamed A. Abosharaf*, Aliaa A. Habib, Abdul Aziz M. Gad and Tarek M. Mohamed*
Affiliation:
- Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt
- Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt
Keywords:
COX-2, resveratrol, Ehrlich ascites carcinoma, cell cycle, apoptosis, EAC model.
Abstract:
Background: The primary goal of researchers interested in the field of oncology continues to
be the development of a new anti-cancer medicine with minimal side effects. Due to their minimal toxicity
and impressive performance, natural source-mediated anti-cancer treatments are attracting a lot of
attention.
Objective: The purpose of the current work was to extract and purify resveratrol from local Leguminosae,
such as peanut, beans, cowpea, lupine, fava bean, and soybean, and then assess its cyclooxygenase-
2 (COX-2) inhibition. The aim was then to evaluate the anticancer potential of extracted resveratrol
individually or combined with doxorubicin against Ehrlich ascites carcinoma (EAC) model.
Methods: Resveratrol was extracted and purified using a silica gel column. The inhibition study of extracted
resveratrol was conducted against COX-2 in vitro. Then, the anti-proliferation impact of resveratrol
alone or combined with doxorubicin was evaluated against the previously established EAC model.
Apoptotic/anti-apoptotic genes and cell cycle arrest were investigated.
Results: After being extracted from peanuts, resveratrol inhibited COX-2 in vitro competitively with an
inhibition constant (Ki) of 0.545 μM, which is extremely close to the theoretically predicted value (0.48
μM) from molecular docking. Further, resveratrol obviously inhibited COX-2 in vivo. Importantly,
resveratrol was able to cause apoptosis by upregulating Bax and downregulating the anti-apoptotic gene
Bcl-2, either by itself or in combination with doxorubicin. Additionally, resveratrol's ability to stop the
cell cycle is evidence of its COX-2-inhibiting antiproliferative properties.
Conclusion: Resveratrol exhibits anticancer potential via inhibition of COX-2, and it could be appropriate
for combinational therapy in vivo.
